I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.
The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion.
We are at a transformational period in oncology; the overall mortality from cancer is gradually declining in the United States.
Peritoneal metastases arise from gastrointestinal and gynecologic malignancies, leading to debilitating symptoms and poor prognoses. They remain one of the most challenging manifestations of advanced malignancies, often leading to significant morbidity and limited treatment options.
This year marks the 49th anniversary of the City of Hope bone marrow transplant program, which was conceived and developed by Ernest Beutler and Karl Blume in 1975, with help and inspiration from E. Donnall Thomas, the 1990 Nobel Laureate in Physiology and Medicine.
With recent leaps in artificial intelligence, there is major potential to turn computing advances into gains for human health.
Cancer care is at an inflection point. The traditional boundaries between academic and community oncology are dissolving, requiring a reimagined approach to patient care and clinical research. At City of Hope, we are implementing a national model that integrates breakthrough research with accessible, advanced treatment across diverse geographic regions.
The thymus gland, in many ways, remains a mystery. The thymic regeneration division of the laboratory of Marcel van den Brink, president of City of Hope Los Angeles and City of Hope National Medical Center, is trying to tease out its secrets.
As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency.
The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
